Baylor College of Medicine

Nicholas Mitsiades

Bert W O'Malley

Qin Feng

Subhamoy Dasgupta

Bin He

Arun Sreekumar

Rainer B Lanz

Sean E Mcguire

Embodiments of the present disclosure concern methods and compositions for prognosis, diagnosis, and/or treatment of prostate cancer or breast cancer, for example. Certain embodiments of the disclosure concern assaying for the expression level of TDRD1. Particular embodiments concern treating an individual with a particular cancer therapy when the expression level of TDRD1 is overexpressed.

Diagnostic/prognostic marker and therapeutic target for cancer

Embodiments of the disclosure include methods and compositions for treatment of prostate cancer, including metastatic prostate cancer or prostate cancer at risk for developing into metastatic prostate cancer, by providing an effective therapy to an individual that has been determined to have elevated levels of SRC-2 (also known as NCOA2, GRIP1 TIF2). In particular cases, sample from an individual known to have prostate cancer is assayed for the risk for developing metastatic prostate cancer and the individual is provided an effective therapy upon determination of elevated levels of SRC-2.

SRC-2 use as metabolic biomarker for diagnosis and treatment of metastatic prostate cancer

Growing community of inventors

Boston, MA, United States of America

Nicholas Mitsiades